CHC – The Cancer & Hematology Centers

AstraZeneca (CAPITELLO-281)

A Phase III Double-Blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterized by PTEN deficiency (CAPItello-281)

Principal Investigator: Dr. Eric Batts

For more information on this trial, read its profile on here.